← All stocks

PULSE BIOSCIENCES, INC.

PLSE Net buying

CIK 0001625101 #1646 in the set updated 17 Sep 2026

Bought (120 mo)

$213.88M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$7.71M

$0.00 on a plan · $6.36M straight out of an exercise

Sold at will

$1.36M

3 of 23 sales

Net

+$206.17M

+$212.52M against sales at will

By person

11 insiders · 211 transactions

1.0×

Paul A. LaViolette holds only 1.0 times base salary in stock. $749.25K of shares against $708.52K in salary for 2025.

Salary from the company's own proxy. The shares are what Paul A. LaViolette last reported holding, valued at $49.95, the price Common Stock was last bought or sold at on the open market here, on 1 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

DUGGAN ROBERT W

Director

$210.07M (83)

—

+$210.07M

48,991,641

68.69%

$2.45B

+2,811%

Danahy Kevin Patrick

Chief Commercial Officer

$50.11K (4)

$3.39M (10) scheduled

−$3.34M

43,298

0.0607%

$2.16M

+40.8%

Zanganeh Mahkam

Director

$2.96M (20)

—

+$2.96M

969,043

1.36%

$48.40M

+133.0%

UECKER DARRIN

Chief Technology Officer

—

$2.34M (7) scheduled

−$2.34M

284,406

0.3988%

$14.21M

+2,531%

Barrett Burke Thomas

Former President and CEO

$85.60K (1)

$871.00K (1)

−$785.40K

63,172

0.0886%

$3.16M

−37.5%

Thaure Thierry B.

Director

—

$581.32K (3) scheduled

−$581.32K

0.0000%

$0.00

—

Greenberg Robert J.

Director

—

$528.11K (2) scheduled

−$528.11K

0.0000%

$0.00

—

LAVIOLETTE PAUL A

Chief Executive Officer

$295.35K (1)

—

+$295.35K

15,000

0.0210%

$749.25K

—

Levinson Mitchell E.

Chief Strategy Officer

$222.17K (19)

—

+$222.17K

106,313

0.1491%

$5.31M

+840.7%

Teplitsky Liane Rae

Chief Operating Officer

$199.94K (4)

—

+$199.94K

4,095

0.0057%

$204.55K

—

Ebbers Ed

EVP & GM, Dermatology

—

39,300

0.0551%

$1.96M

−9.6%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 196

Amendments (4/A) skipped 5

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 20

Sales at will 3

Transactions with no price 0

Shares from compensation/vesting 29,589,146

History held since 16 Nov 2016